Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Recombinant Anti-PD-L1 Monoclonal Antibody Injection (ZKAB001) Combined With Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer

NCT04346914 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.

NCT NCT04346914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04346914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Recombinant Anti-PD-L1 Monoclonal Antibody Injection (ZKAB001) Combined With Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer
Lead sponsor
Lee's Pharmaceutical Limited
Phase
Phase 1
Overall status
Unknown status
Start date
March 8, 2020
Completion date
October 30, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer